BACKGROUND: The additional monitoring (AM)/black triangle concept is aimed to enhance ADR reporting for certain types of medicinal products for which the safety profile is less well established. PURPOSE: The objective of this survey was to assess (a) attitudes towards ADR reporting and reasons for not reporting an ADR and (b) awareness of AM among HCPs, patients or their careers in EU countries. METHODS: An online questionnaire which was available in all EU languages was completed by 2918 responders coming from all EEA countries. RESULTS: The main factors motivating to report an ADR were severity or novelty of the reaction or novelty of the medicine. The main factors for not reporting an ADR was the fact that the ADR is already known (35%), the ADR was not serious (18%) or reporter was not sure if the ADR was related to the medicine (15%). Half of the respondents indicated that they have seen AM statement before. Thirty percent of the responders had correct understanding of the AM concept while 20 % misunderstood the concept. CONCLUSION: Underreporting occurs but it seems this is because of reporter's prioritisation towards certain type of ADRs. AM aims to increase reporting for certain medicines, however, approximately half of responders have seen the AM symbol before and 20% of all responders (independent of their previous awareness) misunderstood the concept.
BACKGROUND: The additional monitoring (AM)/black triangle concept is aimed to enhance ADR reporting for certain types of medicinal products for which the safety profile is less well established. PURPOSE: The objective of this survey was to assess (a) attitudes towards ADR reporting and reasons for not reporting an ADR and (b) awareness of AM among HCPs, patients or their careers in EU countries. METHODS: An online questionnaire which was available in all EU languages was completed by 2918 responders coming from all EEA countries. RESULTS: The main factors motivating to report an ADR were severity or novelty of the reaction or novelty of the medicine. The main factors for not reporting an ADR was the fact that the ADR is already known (35%), the ADR was not serious (18%) or reporter was not sure if the ADR was related to the medicine (15%). Half of the respondents indicated that they have seen AM statement before. Thirty percent of the responders had correct understanding of the AM concept while 20 % misunderstood the concept. CONCLUSION: Underreporting occurs but it seems this is because of reporter's prioritisation towards certain type of ADRs. AM aims to increase reporting for certain medicines, however, approximately half of responders have seen the AM symbol before and 20% of all responders (independent of their previous awareness) misunderstood the concept.
Authors: A J Avery; C Anderson; C M Bond; H Fortnum; A Gifford; P C Hannaford; L Hazell; J Krska; A J Lee; D J McLernon; E Murphy; S Shakir; M C Watson Journal: Health Technol Assess Date: 2011-05 Impact factor: 4.014
Authors: Justina Januskiene; Andrej Segec; Jim Slattery; Georgy Genov; Kelly Plueschke; Xavier Kurz; Peter Arlett Journal: Pharmacoepidemiol Drug Saf Date: 2020-11-08 Impact factor: 2.890
Authors: Justina Januskiene; Andrej Segec; Jim Slattery; Georgy Genov; Kelly Plueschke; Xavier Kurz; Peter Arlett Journal: Pharmacoepidemiol Drug Saf Date: 2020-11-08 Impact factor: 2.890
Authors: Andrej Segec; Jim Slattery; Daniel R Morales; Justina Januskiene; Xavier Kurz; Peter Arlett Journal: Pharmacoepidemiol Drug Saf Date: 2020-12-08 Impact factor: 2.732